These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15113037)

  • 1. Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic and remetastatic cell lines?
    Morioka CY; Saito S; Machado MC; Ohzawa K; Kubrusly MS; Cunha JE; Watanabe A
    In Vivo; 2004; 18(2):113-7. PubMed ID: 15113037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of invasion of a hamster pancreatic cancer cell line by antisense oligonucleotides mutation-matched to K-ras gene.
    Morioka CY; Machado MC; Saito S; Nakada Y; Matheus AS; Jukemura J; Bacchella T; Takahara T; Watanabe A
    In Vivo; 2005; 19(3):535-8. PubMed ID: 15875772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different pattern of metastasis in liver implanted pancreatic cancer between young and old Syrian golden hamsters.
    Morioka CY; Saito S; Machado MC; Jukemura J; Bacchella T; Watanabe A
    In Vivo; 2005; 19(3):639-41. PubMed ID: 15875787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
    Hatanaka K; Suzuki K; Miura Y; Yoshida K; Ohnami S; Kitade Y; Yoshida T; Aoki K
    J Gene Med; 2004 Oct; 6(10):1139-48. PubMed ID: 15452878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The study of the effect of antisense oligonucleotide specific to K-ras point mutation on human pancreatic carcinoma cell PC-2].
    Wang YX; Gao L; Ji ZZ
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(21):1387-90. PubMed ID: 16318775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneously inoculated cells and implanted pancreatic cancer tissue show different patterns of metastases in Syrian golden hamsters.
    Morioka CY; Saito S; Ohzawa K; Asano S; Hibino Y; Nakada Y; Kita KI; Watanabe A
    JOP; 2000 Nov; 1(4):183-90. PubMed ID: 11856860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
    Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T
    Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of metastatic behavior of parental and metastatic pancreatic cancer cell lines in Syrian golden hamsters.
    Morioka CY; Saito S; Machado MC; Ohzawa K; Yamago GI; Bacchella T; Watanabe A
    In Vivo; 2004; 18(1):63-6. PubMed ID: 15011753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
    Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T
    Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice.
    Hamada K; Monnai M; Kawai K; Nishime C; Kito C; Miyazaki N; Ohnishi Y; Nakamura M; Suemizu H
    Int J Oncol; 2008 Jan; 32(1):153-9. PubMed ID: 18097554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models.
    Himeno Y; Etoh T; Matsumoto T; Ohta M; Nishizono A; Kitano S
    Int J Oncol; 2005 Oct; 27(4):901-6. PubMed ID: 16142304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Return trip" metastases from the liver to the pancreas in Syrian golden hamsters.
    Morioka CY; Saito S; Watanabe A
    In Vivo; 2000; 14(3):467-9. PubMed ID: 10904884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer.
    Xing HR; Cordon-Cardo C; Deng X; Tong W; Campodonico L; Fuks Z; Kolesnick R
    Nat Med; 2003 Oct; 9(10):1266-8. PubMed ID: 12960962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
    Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
    Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
    Miura Y; Ohnami S; Yoshida K; Ohashi M; Nakano M; Ohnami S; Fukuhara M; Yanagi K; Matsushita A; Uchida E; Asaka M; Yoshida T; Aoki K
    Cancer Lett; 2005 Jan; 218(1):53-62. PubMed ID: 15639340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical nude mouse metastatic model for highly malignant human pancreatic cancer.
    An Z; Wang X; Kubota T; Moossa AR; Hoffman RM
    Anticancer Res; 1996; 16(2):627-31. PubMed ID: 8687107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitary effects of antisense oligonucleotide specific to K-ras point mutation on the target gene expression in human pancreatic carcinoma cells.
    Wang YX; Gao L; Ji ZZ
    Chin Med J (Engl); 2007 Aug; 120(16):1448-50. PubMed ID: 17825176
    [No Abstract]   [Full Text] [Related]  

  • 18. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
    Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
    Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer.
    Weiss FU; Marques IJ; Woltering JM; Vlecken DH; Aghdassi A; Partecke LI; Heidecke CD; Lerch MM; Bagowski CP
    Gastroenterology; 2009 Dec; 137(6):2136-45.e1-7. PubMed ID: 19747919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
    Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.